Clinical meaning
The NP applies the CDC US Medical Eligibility Criteria (US MEC) for contraceptive prescribing, integrates HRT risk-benefit analysis, manages UTI prophylaxis, ensures adequate prenatal supplementation, and maintains awareness of teratogenic medications. The US MEC classifies contraceptive safety into 4 categories: Category 1 (no restriction), Category 2 (advantages generally outweigh risks), Category 3 (risks generally outweigh advantages -- method not usually recommended), and Category 4 (unacceptable health risk -- method contraindicated). Key US MEC Category 4 conditions for combined hormonal contraceptives (CHCs) include: smoking 15+ cigarettes/day in women over 35, current or history of VTE/PE, known thrombogenic mutations, current or history of ischemic heart disease or stroke, migraine with aura at any age, breast cancer (current), complicated valvular heart disease, and systolic BP 160+ or diastolic 100+. Progestin-only methods (pills, implant, IUD, injection) have fewer Category 4 restrictions, making them safer for many women with CHC contraindications. Hormone replacement therapy (HRT) decision-making integrates the WHI findings: combined estrogen-progestin HRT increases VTE risk (HR 2.06), stroke risk (HR 1.41), and breast cancer risk after approximately 5 years of use (HR 1.26); estrogen-only HRT in hysterectomized women does not increase breast cancer risk and may decrease it. The timing hypothesis supports initiating HRT within 10 years of menopause onset or before age 60 for favorable cardiovascular benefit-risk profile. Recurrent UTI prophylaxis in women involves identifying modifiable risk factors and prescribing continuous low-dose antibiotic prophylaxis (nitrofurantoin 50-100mg nightly or TMP-SMX half-strength nightly) or postcoital prophylaxis for coitus-related recurrent UTIs. Prenatal vitamin prescribing ensures folic acid 400-800 mcg daily (or 4mg daily for women with prior NTD-affected pregnancy) beginning at least 1 month before conception and continuing through the first trimester to prevent neural tube defects. Teratogenic medication awareness requires identifying and managing FDA Category X medications before and during pregnancy: isotretinoin (iPLEDGE program), warfarin (especially weeks 6-12, causing nasal hypoplasia and chondrodysplasia punctata), methotrexate, ACE inhibitors and ARBs (second/third trimester renal agenesis), statins, valproic acid (neural tube defects), and lithium (Ebstein anomaly).